Abstract
Patients with dementia frequently experience comorbid behavioral and psychiatric symptoms that are harmful to both patients and their caregivers and contribute to the high healthcare costs associated with Alzheimer’s dementia. Despite their frequent use in the past, there is limited evidence to support the efficacy of first-generation antipsychotics. Second-generation antipsychotics may be modestly helpful for reducing global neuropsychiatric symptoms, psychosis, and agitation/aggression but are associated with potentially serious adverse reactions. The decision to utilize an antipsychotic requires thoughtful consideration of the potential risks and benefits for the individual patient.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
